151 related articles for article (PubMed ID: 18084259)
1. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis.
Kartha RV; Sundram UN
Mod Pathol; 2008 Feb; 21(2):96-104. PubMed ID: 18084259
[TBL] [Abstract][Full Text] [Related]
2. Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma.
Swick BL; Srikantha R; Messingham KN
J Cutan Pathol; 2013 Jul; 40(7):623-30. PubMed ID: 23621836
[TBL] [Abstract][Full Text] [Related]
3. Association of Merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in Merkel cell carcinoma.
Waltari M; Sihto H; Kukko H; Koljonen V; Sankila R; Böhling T; Joensuu H
Int J Cancer; 2011 Aug; 129(3):619-28. PubMed ID: 20949558
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
Reis RM; Martins A; Ribeiro SA; Basto D; Longatto-Filho A; Schmitt FC; Lopes JM
Cell Oncol; 2005; 27(5-6):319-26. PubMed ID: 16373964
[TBL] [Abstract][Full Text] [Related]
5. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma.
Brunner M; Thurnher D; Pammer J; Geleff S; Heiduschka G; Reinisch CM; Petzelbauer P; Erovic BM
Mod Pathol; 2008 Jul; 21(7):876-84. PubMed ID: 18408656
[TBL] [Abstract][Full Text] [Related]
6. Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations.
Cao D; Antonescu C; Wong G; Winter J; Maitra A; Adsay NV; Klimstra DS; Hruban RH
Mod Pathol; 2006 Sep; 19(9):1157-63. PubMed ID: 16778826
[TBL] [Abstract][Full Text] [Related]
7. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
8. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
9. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
[TBL] [Abstract][Full Text] [Related]
10. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.
Andea AA; Patel R; Ponnazhagan S; Kumar S; DeVilliers P; Jhala D; Eltoum IE; Siegal GP
Hum Pathol; 2010 Oct; 41(10):1405-12. PubMed ID: 20594584
[TBL] [Abstract][Full Text] [Related]
11. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
12. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
[TBL] [Abstract][Full Text] [Related]
13. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2008 Feb; 35(2):197-202. PubMed ID: 18190445
[TBL] [Abstract][Full Text] [Related]
14. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
[TBL] [Abstract][Full Text] [Related]
16. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
18. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
19. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
[TBL] [Abstract][Full Text] [Related]
20. C-KIT and PDGFRA zygosity in gastrointestinal stromal tumors: Correlation with tumor site, tumor size, exon, and CD117 immunohistochemistry.
Wallander ML; Willmore-Payne C; Layfield LJ
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):21-7. PubMed ID: 20823768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
